What Is Ureaplasma? How It Affects Reproductive Health

Ureaplasma is a genus of tiny bacteria that live in the urogenital tracts of a large share of the adult population without causing any symptoms at all. Somewhere between one in ten and one in three sexually active adults carry it, depending on the study and the population sampled. The tricky part is that the same organism sitting harmlessly in one person can contribute to urethritis, fertility problems, pregnancy complications, or serious infections in immunocompromised patients. That gap between “common colonizer” and “occasional pathogen” is what makes Ureaplasma one of the more confusing organisms in reproductive and sexual health, and it has driven a genuine debate among clinicians about when to test for it and when to leave it alone.

What Ureaplasma Is and Why It Is Unusual

Ureaplasma belongs to a class of organisms called Mollicutes, a group defined by having no cell wall and a very small genome compared with other bacteria.¹ The lack of a cell wall is biologically important because it means antibiotics that work by attacking bacterial cell walls, like penicillin and other beta-lactams, are completely useless against Ureaplasma. That narrows the treatment options from the outset.

Two species infect humans: Ureaplasma parvum and Ureaplasma urealyticum. These two were originally lumped together under one name, and older literature often does not distinguish between them. The distinction matters because the species do not behave identically. A systematic review and meta-analysis found that U. urealyticum, but not U. parvum, is a genuine cause of nongonococcal urethritis in men.² Meanwhile, U. parvum shows up far more frequently in routine samples, often as a bystander. Studies comparing the two in clinical specimens using PCR consistently find that U. parvum is the more common species in the genital tract.³

The organism’s evolutionary history helps explain why it is such a ubiquitous colonizer. Mollicutes have undergone extreme genome reduction over time, shedding genes for many independent metabolic functions and becoming deeply reliant on the host for nutrients. Research on Ureaplasma protein interaction networks suggests horizontal gene transfer between different species sharing the urogenital tract enabled this simplification, essentially locking the organism into a lifestyle of quiet dependence on its host.⁴

How Common Asymptomatic Carriage Really Is

Prevalence numbers for Ureaplasma vary widely by population, geography, and testing method. In a study of nearly 5,800 asymptomatic individuals in Korea, roughly one in ten women tested positive for Ureaplasma species on culture, while fewer than one in 200 men were positive.⁵ A smaller study of asymptomatic women in northern Greece found a carriage rate of about 16%, concentrated among women of reproductive age.⁶ Some studies of sexually active populations report figures north of 40%.

The point these numbers collectively make is that carrying Ureaplasma is common and, for most people, unremarkable. The organism is part of the normal genital flora in a large minority of adults. This is precisely what makes it hard to classify as a straightforward pathogen. A European STI guidelines board position statement put it plainly: asymptomatic carriage is common, and the majority of carriers never develop any disease.⁷

Effects on Male Reproductive and Urinary Health

The strongest evidence linking Ureaplasma to disease in men concerns nongonococcal urethritis, or NGU, which is inflammation of the urethra not caused by gonorrhea. The association is strongest for U. urealyticum specifically, and it gets more interesting when you look at who is affected. A case-control study found that U. urealyticum was only weakly associated with NGU when all men were analyzed together, but the association became much stronger in men with fewer lifetime sexual partners. Among men with fewer than five partners, the odds of NGU were roughly five to six times higher if U. urealyticum was present.⁸ One interpretation is that men with more partners may develop a degree of immune tolerance to the organism over time.

There is also a growing body of evidence connecting U. urealyticum infection to reduced semen quality. A systematic review and meta-analysis found that men positive for U. urealyticum had lower sperm concentration, reduced total motility, lower normal morphology, and higher levels of inflammatory markers and DNA fragmentation in their semen.⁹ A separate large study confirmed the association with lower sperm concentrations, lower forward motility, and reduced normal morphology.¹⁰ The mechanism appears to involve the organism triggering a local immune response that produces inflammatory cytokines and raises levels of white blood cells in seminal fluid, which in turn damages sperm.

Whether treating U. urealyticum in infertile men reliably improves their semen parameters is less settled. The data so far demonstrate the association clearly, but randomized treatment trials with fertility outcomes as the endpoint remain scarce. Still, the role of Ureaplasma in male infertility remains “highly controversial,” partly because clinicians have historically had trouble separating pathogenic infection from harmless colonization.¹¹

Female Reproductive Health and Pelvic Infection

In women, Ureaplasma has been implicated in several conditions affecting the reproductive tract. Among women diagnosed with pelvic inflammatory disease, one study found the Ureaplasma infection rate was more than 30 times higher than that of the related organism Mycoplasma hominis.¹² Ureaplasma also appeared among the most commonly cited bacterial genera in a review of bacteria associated with endometritis, inflammation of the uterine lining.¹³

An important wrinkle is that Ureaplasma does not operate in isolation. Its presence in the vaginal microbiome correlates with shifts in the broader microbial community. Colonization with U. parvum has been linked to more than four times the odds of bacterial vaginosis involving Gardnerella vaginalis, a near tripling of M. hominis prevalence, and higher rates of yeast infections.¹⁴ Whether Ureaplasma is causing those shifts or simply thriving in a vaginal environment already disrupted by other factors is not fully resolved, but the association is consistent.

One protective factor appears to be Lactobacillus. Research on the vaginal microbiome during pregnancy found that when Ureaplasma and another bacteria called Prevotella coexisted alongside a healthy Lactobacillus population, pregnancy outcomes were not affected. The authors suggested Lactobacillus may have a protective effect that keeps Ureaplasma in check.¹⁵ This fits with the broader understanding that a Lactobacillus-dominant vaginal microbiome acts as a buffer against various opportunistic organisms.

Pregnancy, Preterm Birth, and Miscarriage

The stakes of Ureaplasma colonization rise considerably during pregnancy. A meta-analysis found that Ureaplasma-positive status during pregnancy roughly tripled the odds of preterm birth, nearly tripled the odds of chorioamnionitis (inflammation of the fetal membranes), and doubled the odds of premature rupture of membranes.¹⁶ In a study of moderately preterm and late-preterm births, Ureaplasma in placental tissue was strongly associated with histologically confirmed chorioamnionitis, found in roughly two-thirds of Ureaplasma-positive placentas. Importantly, that placental inflammation was significantly linked to spontaneous preterm birth.¹⁷

The connection to miscarriage is also being investigated. A study examining placental tissue from women who miscarried found that detection of U. parvum in the placenta was associated with roughly six times the odds of spontaneous abortion.¹⁸ In women with a history of recurrent pregnancy loss, the relative abundance of Ureaplasma in the uterine lining was an independent risk factor both for subsequent miscarriage with a chromosomally normal embryo and for preterm delivery.¹⁹

These findings do not mean that every pregnant person who tests positive for Ureaplasma will have complications. Most will not. But the data do suggest that in the context of inflammation and disrupted microbial balance, Ureaplasma can be a meaningful contributor to adverse outcomes rather than an innocent bystander.

Risks to Newborns

Ureaplasma can be transmitted from mother to infant during birth, and in premature infants especially, this colonization can lead to serious consequences. The condition most studied is bronchopulmonary dysplasia, or BPD, a chronic lung disease of prematurity. The link between Ureaplasma colonization of the newborn respiratory tract and BPD has been debated for over two decades.²⁰ The prevailing model is that Ureaplasma triggers a sustained inflammatory response in the immature lung, which is then worsened by mechanical ventilation and supplemental oxygen, ultimately impairing normal lung development.

A clinical study comparing Ureaplasma-positive and Ureaplasma-negative preterm infants found a BPD rate of 25% in the colonized group versus 6% in the uncolonized group. Ureaplasma colonization was independently associated with BPD even after adjusting for other risk factors like gestational age and ventilator days.²¹ The same meta-analysis that quantified pregnancy risks found that maternal Ureaplasma positivity more than doubled the odds of the infant developing BPD.²²

Beyond the lungs, neonatal central nervous system infections caused by Ureaplasma are rare but alarming. A multicenter surveillance study found that even after successful eradication of the infection, all affected infants showed developmental delay, and several were later diagnosed with structural epilepsy.²³

How Ureaplasma Evades the Immune System

One reason Ureaplasma can persist for so long in the body is its ability to change its surface appearance. The organism’s main surface protein, called the multiple banded antigen or MBA, undergoes frequent recombination events that alter the protein’s structure. Research has shown these genetic rearrangements are dynamic and produce a wide range of antigenic variants, allowing the organism to dodge immune recognition.²⁴ In a sheep model of intra-amniotic infection, ureaplasmas were observed to undergo MBA size variation in living tissue, a potential strategy to prevent the immune system from clearing them.²⁵

On top of antigenic variation, Ureaplasma can form biofilms, protective communities of bacteria embedded in a matrix that shields them from both antibiotics and the host immune response. Biofilm formation has been shown to increase antibiotic resistance and favor long-term persistence in chronically infected or colonized patients.²⁶ These twin strategies, surface disguise and biofilm shelter, help explain why Ureaplasma infections can be stubborn even with appropriate antibiotic therapy.

Testing and Why It Is Not Straightforward

Given how common asymptomatic carriage is, the first question around testing is not “how” but “whether.” The European STI guidelines board explicitly recommended against routine testing of asymptomatic men and women, arguing that the widespread testing, detection, and subsequent treatment of these bacteria in some clinical settings risks driving antibiotic resistance while providing no clear benefit.²⁷ In some countries, however, commercial STI panels now routinely include Ureaplasma, leading to positive results in healthy people and a cycle of anxiety and unnecessary treatment.

When testing is warranted, the method matters. Traditional liquid culture kits are fast but imprecise. One study found a false-positive rate of about 7% for liquid culture and recommended confirming suspicious results with a more specific method.²⁸ PCR-based tests are more sensitive and can distinguish between U. parvum and U. urealyticum, which culture alone cannot reliably do. Quantitative real-time PCR had a higher positive detection rate than either culture methods or conventional PCR in head-to-head comparisons.²⁹ A separate study using a multiplex quantitative PCR assay found sensitivities above 89% across male urethral swabs, female urethral swabs, and cervical swabs, with specificities near or at 100% in most specimen types.³⁰

The practical takeaway: if you have symptoms such as urethral discharge, pelvic pain, or recurrent pregnancy loss, and your clinician suspects Ureaplasma might be involved, a PCR-based test that differentiates the two species is far more informative than a basic culture panel. A positive result for U. parvum alone in the absence of symptoms is generally not a reason for treatment.

Treatment and the Problem of Resistance

Because Ureaplasma has no cell wall, the antibiotics used against it are those targeting protein synthesis or DNA replication. Doxycycline, a tetracycline, is the most commonly used first-line drug. In a mouse model of Ureaplasma lung infection, doxycycline was the most effective agent and worked against all study strains except one that carried a specific resistance gene. It outperformed both azithromycin and levofloxacin.³¹

Azithromycin is another option, often prescribed when doxycycline is contraindicated (as in pregnancy). A meta-analysis comparing azithromycin to other treatments for U. urealyticum found it performed comparably, with no significant advantage or disadvantage.³² Fluoroquinolones such as levofloxacin and moxifloxacin are considered second-line options and are generally reserved for resistant cases.

Resistance is a real and growing concern. Tetracycline resistance in Ureaplasma is primarily driven by a gene called tet(M), which produces a protein that interferes with tetracycline’s ability to bind its target on the bacterial ribosome. The gene sits on a transposon, a mobile genetic element, meaning it can spread between organisms.³³ This mobility is why unnecessary treatment of asymptomatic carriers is worrying to public health experts: treating a person who doesn’t need it adds selection pressure that can breed resistant strains, making treatment harder for people who genuinely do need it.

Dangerous Infections in Immunocompromised Patients

For most healthy adults, Ureaplasma sits quietly in the genital tract. But in people with severely weakened immune systems, particularly organ transplant recipients and those undergoing chemotherapy or stem cell transplants, Ureaplasma can disseminate through the bloodstream and cause life-threatening disease. The most dramatic presentation is hyperammonemia syndrome, a dangerous buildup of ammonia in the blood that leads to encephalopathy, brain swelling, and seizures.

Ureaplasma produces ammonia as a byproduct of its metabolism because it breaks down urea using an enzyme called urease (this is actually where the genus name comes from). Normally, the amount of ammonia produced in the genital tract is trivial. But when the organism spreads systemically in someone who cannot mount an immune response, ammonia levels can spike to dangerous levels. Case reports describe transplant patients developing new-onset seizures and diffuse brain swelling from this mechanism. In one series of three immunosuppressed patients who developed hyperammonemia with status epilepticus from Ureaplasma or related Mycoplasma infection, none survived despite aggressive treatment.³⁴

Survival is possible with early recognition and treatment. A case report described a stem cell transplant recipient who developed hyperammonemia from U. urealyticum and was diagnosed through molecular testing. She was treated with doxycycline and supportive care and recovered neurologically, though she later developed relapsing septic arthritis in the joints, another known extragenital manifestation of disseminated Ureaplasma.³⁵ Another patient who developed hyperammonemia years after a stem cell transplant, in the setting of chronic immunosuppressive therapy, achieved full neurological recovery after treatment with ciprofloxacin and doxycycline.³⁶

These cases are rare, but they have prompted transplant centers to add Ureaplasma to the list of organisms to consider when an immunocompromised patient presents with unexplained hyperammonemia or encephalopathy. Standard blood cultures will not detect it because the organism grows poorly on conventional media and lacks a cell wall. Molecular testing, specifically PCR, is essential for diagnosis in these situations.

The Screening Debate and Why Context Matters

If you have ever received a positive Ureaplasma result from a commercial STI panel and been told you need antibiotics, it is worth understanding the argument against that approach. The European position statement against routine screening rests on a straightforward cost-benefit analysis: there is currently no evidence that detecting and treating Ureaplasma in asymptomatic people does more good than harm. The potential harms include driving antibiotic resistance in Ureaplasma itself and in other bacteria sharing the same environment, causing unnecessary anxiety, and generating cost for individuals and healthcare systems.³⁷

That said, context changes the calculation. If you are experiencing recurrent urethritis that has not responded to standard gonorrhea and chlamydia treatment, testing for U. urealyticum specifically is reasonable. If you are struggling with infertility and your semen analysis shows abnormalities along with elevated inflammatory markers, Ureaplasma testing adds useful information. If you have had multiple pregnancy losses and your reproductive immunology workup has come up empty, investigating the endometrial microbiome for Ureaplasma dominance could be a next step. And for transplant patients with unexplained neurological decline, Ureaplasma should be on the differential diagnosis even though it was never thought of as a neurological pathogen.

The organism sits in a gray zone that is genuinely frustrating for patients and clinicians alike. It is neither a clear-cut pathogen like gonorrhea, where a positive result always warrants treatment, nor a harmless commensal like most Lactobacillus species. The evidence increasingly supports that its behavior depends on the species involved, the bacterial load, the surrounding microbial community, the anatomical site, and the immune status of the host. That is not a satisfying answer when you are staring at a lab result, but it is the honest one.